Gabapentin Tablet
Product Images NDC 71335-3143

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-3143). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clcr (Equation)

A mathematical formula labeled CLCr for calculating creatinine clearance. The formula is presented as [(140 - age in years) × weight in kg] divided by [72 × serum creatinine in mg/dL], multiplied by 0.85 for female patients. This calculation is typically used in medication dosing adjustments.*

FDA Label Image

Figure-1 (Figure1)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' showing mean pain scores over an 8-week period. Two lines compare placebo and gabapentin 3600 mg/day groups. The graph indicates mean pain scores on the vertical axis (0-10 scale) and weeks on the horizontal axis, with a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure-2 (Figure2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. It compares placebo and gabapentin dosed at 1800 mg/day and 2400 mg/day, with a 3-week dose titration period and a 4-week fixed dose period. Mean pain scores decrease over time for both gabapentin doses compared to placebo.*

FDA Label Image

Figure-3 (Figure3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) groups in two studies. The chart shows percentages of responders, with Gabapentin groups having higher response rates (29%, 32%, and 34%) compared to placebo (12% and 14%), indicating statistical significance (p < 0.01 and p < 0.001).*

FDA Label Image

Figure-4 (Figure4)

A scatter plot showing responder rate differences from placebo by daily dose of gabapentin in milligrams, for three separate studies labeled a, b, and c. The vertical axis represents percentage difference, and the horizontal axis shows daily dose values including 600 mg, 900 mg, 1200 mg, and 1800 mg. Data points for each study are shown with different shades, depicting response rates in patients aged 12 and older with partial seizures.*

FDA Label Image

Label (Lbl713353143)

Label for Gabapentin Tablets, USP 600 mg oral tablets. The label shows the NDC 71335-3143-1 and indicates a package of 90 tablets. It is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA and manufactured by Ascent Pharmaceuticals, Inc. Storage instructions and medication guide information are also noted.*

FDA Label Image

Struc (Struct)

Chemical structure of gabapentin showing a cyclohexane ring bonded to amino (CH2NH2) and carboxymethyl (CH2CO2H) groups as part of its molecular composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.